All In Biotech

Drug Trial Radar · NCT07519070

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Apr 5, 2026

Primary completion

Apr 5, 2028

Study completion Dec 30, 2028

Sponsor

Sponsor type
Industry
First posted
Apr 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of HSK44459 tablets in patients with idiopathic pulmonary fibrosis (IPF).

Conditions

  • IPF

Interventions

  • HSK44459Drug

    HSK44459 Without IPF background therapy

  • HSK44459Drug

    HSK44459 With Nintedanib

  • HSK44459Drug

    HSK44459 With Pirfenidone

  • PlaceboDrug

    Placebo Without IPF background therapy

  • PlaceboDrug

    Placebo With Nintedanib

  • PlaceboDrug

    Placebo With Pirfenidone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in FVC from baseline at Week 52Time frame: Week 52

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.